Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 56.12 USD 1.15% Market Closed
Market Cap: 3.4B USD
Have any thoughts about
Rhythm Pharmaceuticals Inc?
Write Note

Rhythm Pharmaceuticals Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Rhythm Pharmaceuticals Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Total Liabilities
$210.9m
CAGR 3-Years
84%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%
No Stocks Found

Rhythm Pharmaceuticals Inc
Glance View

Market Cap
3.4B USD
Industry
Biotechnology

Rhythm Pharmaceuticals Inc. emerged with a resolute focus, aiming to transform the landscape for individuals grappling with rare genetic disorders of obesity. Founded on the premise that certain predispositions to obesity are deeply rooted in genetics, Rhythm embarked on a journey to develop treatments that target the melanocortin-4 receptor (MC4R) pathway. This pathway plays a critical role in regulating hunger, energy expenditure, and overall body weight. Their flagship product, Imcivree (setmelanotide), gained approval and marked a significant stride forward for the company. It is specifically designed to address the underlying genetic causes of obesity, offering hope to patients who previously had limited therapeutic options. The business model of Rhythm Pharmaceuticals is patient-centric, grounded in innovation and strategic collaborations. They generate revenue through the commercialization of Imcivree, facilitated by partnerships with healthcare providers and institutions that benefit from the specialized treatment they offer. Additionally, Rhythm actively invests in research and development, continually seeking to expand the applicability of their products to other genetic obesity-related conditions. By maintaining a robust pipeline and leveraging scientific advancements, the company positions itself as a pioneer in addressing an underserved niche, sustainably growing through targeted drug development and market expansion initiatives.

RYTM Intrinsic Value
43.71 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Rhythm Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
210.9m USD

Based on the financial report for Sep 30, 2024, Rhythm Pharmaceuticals Inc's Total Liabilities amounts to 210.9m USD.

What is Rhythm Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
49%

Over the last year, the Total Liabilities growth was 35%. The average annual Total Liabilities growth rates for Rhythm Pharmaceuticals Inc have been 84% over the past three years , 49% over the past five years .

Back to Top